Literature DB >> 22619041

Mechanistic determinants of biotherapeutics absorption following SC administration.

Wolfgang F Richter1, Suraj G Bhansali, Marilyn E Morris.   

Abstract

The subcutaneous (SC) route is of growing interest for the administration of biotherapeutics. Key products on the biotherapeutic market such as insulins, but also several immunoglobulins or Fc-fusion proteins, are administered SC. Despite the importance of the SC route, the available knowledge about the processes involved in the SC absorption of biotherapeutics is limited. This review summarizes available information on the physiology of the SC tissue and on the pharmacokinetic processes after SC administration including "first pass catabolism" at the administration site as well as transport in the extracellular matrix of the SC tissue, followed by absorption into the blood circulation or the lymphatic system. Both monoclonal antibodies and other biotherapeutics are discussed. Determinants of absorption after SC administration are summarized including compound properties such as charge or molecular weight. Scale-up of animal data to humans is discussed, including the current shortcomings of empirical scaling approaches and the lack of suitable mechanistic approaches.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22619041      PMCID: PMC3385825          DOI: 10.1208/s12248-012-9367-0

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  95 in total

Review 1.  Structure, function, and molecular control of the skin lymphatic system.

Authors:  M Skobe; M Detmar
Journal:  J Investig Dermatol Symp Proc       Date:  2000-12

2.  Lymphatic absorption is a significant contributor to the subcutaneous bioavailability of insulin in a sheep model.

Authors:  S A Charman; D N McLennan; G A Edwards; C J Porter
Journal:  Pharm Res       Date:  2001-11       Impact factor: 4.200

Review 3.  The physiology of the lymphatic system.

Authors:  M A Swartz
Journal:  Adv Drug Deliv Rev       Date:  2001-08-23       Impact factor: 15.470

Review 4.  Liposomes to target the lymphatics by subcutaneous administration.

Authors:  C Oussoren; G Storm
Journal:  Adv Drug Deliv Rev       Date:  2001-08-23       Impact factor: 15.470

Review 5.  Lymphatic transport of proteins after s.c. injection: implications of animal model selection.

Authors:  C J Porter; G A Edwards; S A Charman
Journal:  Adv Drug Deliv Rev       Date:  2001-08-23       Impact factor: 15.470

6.  Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous dose administration in cynomolgus monkeys.

Authors:  Rohini Ramakrishnan; Wing K Cheung; Francis Farrell; Linda Joffee; William J Jusko
Journal:  J Pharmacol Exp Ther       Date:  2003-04-03       Impact factor: 4.030

7.  Structure of the rat subcutaneous connective tissue in relation to its sliding mechanism.

Authors:  Seiichi Kawamata; Junya Ozawa; Masakazu Hashimoto; Tomoyuki Kurose; Harumichi Shinohara
Journal:  Arch Histol Cytol       Date:  2003-08

8.  Pharmacokinetics of recombinant human leukemia inhibitory factor in sheep.

Authors:  Alicia M Segrave; Donald E Mager; Susan A Charman; Glenn A Edwards; Christopher J H Porter
Journal:  J Pharmacol Exp Ther       Date:  2004-02-10       Impact factor: 4.030

9.  Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys.

Authors:  K McCarthy; P Stewart; J Sigman; M Read; J C Keith; K M Brinkhous; T C Nichols; R G Schaub
Journal:  Thromb Haemost       Date:  2002-05       Impact factor: 5.249

10.  Pharmacokinetic model to describe the lymphatic absorption of r-metHu-leptin after subcutaneous injection to sheep.

Authors:  Danielle N McLennan; Christopher J H Porter; Glenn A Edwards; Maria Brumm; Steven W Martin; Susan A Charman
Journal:  Pharm Res       Date:  2003-08       Impact factor: 4.200

View more
  86 in total

Review 1.  Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides.

Authors:  Lei Diao; Bernd Meibohm
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

2.  Interspecies pharmacokinetic modeling of subcutaneous absorption of rituximab in mice and rats.

Authors:  Leonid Kagan; Jie Zhao; Donald E Mager
Journal:  Pharm Res       Date:  2014-05-23       Impact factor: 4.200

3.  Measuring tissue back-pressure--in vivo injection forces during subcutaneous injection.

Authors:  Andrea Allmendinger; Robert Mueller; Edward Schwarb; Mark Chipperfield; Joerg Huwyler; Hanns-Christian Mahler; Stefan Fischer
Journal:  Pharm Res       Date:  2014-12-24       Impact factor: 4.200

4.  A PBPK workflow for first-in-human dose selection of a subcutaneously administered pegylated peptide.

Authors:  Elliot Offman; Andrea N Edginton
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-02-04       Impact factor: 2.745

Review 5.  Proteolysis and Oxidation of Therapeutic Proteins After Intradermal or Subcutaneous Administration.

Authors:  Ninad Varkhede; Rupesh Bommana; Christian Schöneich; M Laird Forrest
Journal:  J Pharm Sci       Date:  2019-08-10       Impact factor: 3.534

6.  Multiphysics Modeling and Simulation of Subcutaneous Injection and Absorption of Biotherapeutics: Model Development.

Authors:  Fudan Zheng; Peng Hou; Clairissa D Corpstein; Lei Xing; Tonglei Li
Journal:  Pharm Res       Date:  2021-04-02       Impact factor: 4.200

7.  A Potent Branched-Tail Lipid Nanoparticle Enables Multiplexed mRNA Delivery and Gene Editing In Vivo.

Authors:  Khalid A Hajj; Jilian R Melamed; Namit Chaudhary; Nicholas G Lamson; Rebecca L Ball; Saigopalakrishna S Yerneni; Kathryn A Whitehead
Journal:  Nano Lett       Date:  2020-06-09       Impact factor: 11.189

Review 8.  Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.

Authors:  Miroslav Dostalek; Iain Gardner; Brian M Gurbaxani; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

9.  Subcutaneous Site-of-Absorption Study with the Monoclonal Antibody Tocilizumab in Minipigs: Administration Behind Ear Translates Best to Humans.

Authors:  Wolfgang F Richter; Hans-Peter Grimm; Marie-Hélène Gouy; Susi Søgaard; Caroline Kreuzer; Uwe Wessels; Dragomir Draganov; Chris Muenzer; Tonio Hoche
Journal:  AAPS J       Date:  2020-04-03       Impact factor: 4.009

10.  Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics.

Authors:  Daniela Bumbaca Yadav; Vikas K Sharma; Charles Andrew Boswell; Isidro Hotzel; Devin Tesar; Yonglei Shang; Yong Ying; Saloumeh K Fischer; Jane L Grogan; Eugene Y Chiang; Konnie Urban; Sheila Ulufatu; Leslie A Khawli; Saileta Prabhu; Sean Joseph; Robert F Kelley
Journal:  J Biol Chem       Date:  2015-10-21       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.